A trio of Swiss biotechnology companies is advancing diverse therapeutic pipelines, with recent developments spanning inflammatory skin disease, immune‑mediated hair loss, and hard‑to‑treat cancers. Together, these milestones highlight how distinct technology platforms are moving from concept to clinically validated potential.
According to StartUpTicker.ch, MoonLake Immunotherapeutics, which concentrates on inflammatory disorders, has achieved a major regulatory step: the U.S. Food and Drug Administration has granted Fast Track designation to its lead candidate sonelokimab for moderate to severe palmoplantar pustulosis (PPP). PPP is a chronic condition that causes pustular lesions on the palms and soles, often leading to pain and functional impairment. Fast Track status, awarded on the back of positive Phase 2 LEDA data, is reserved for therapies that address serious diseases with limited treatment choices and is designed to streamline development and review.
Sonelokimab (M1095) is an investigational 40 kDa humanized Nanobody® engineered from three heavy‑chain‑only antibody domains joined by flexible glycine‑serine linkers. It targets interleukin‑17 (IL‑17), a key cytokine driving inflammation. Nanobody® constructs represent a newer class of antibody‑derived drugs, their compact size allows better tissue access, they are comparatively robust under temperature variation, and they are amenable to efficient manufacturing. Their modular format also enables multivalent designs and custom target combinations, supporting more tailored therapeutic strategies.
In immuno‑dermatology, Alys Pharmaceuticals has reported new scientific validation for its lead program. A recent article in Nature Communications describes ALY‑101, a small interfering RNA (siRNA) conjugated to a lipid, designed for local action in the skin. ALY‑101 is in Phase 2a clinical testing for patchy alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, causing hair loss. The publication shows that the siRNA persists in cutaneous tissue for more than two months, indicating durable presence at the site of action and reinforcing its promise as a long‑acting treatment approach.
On the oncology front, iOnctura has showcased its leading cancer asset in a paper in Molecular Oncology. The company is developing roginolisib, an oral precision small molecule that acts as a novel allosteric modulator of PI3Kδ. Unlike traditional PI3Kδ inhibitors, roginolisib is designed to deliver strong anti‑tumor effects while minimizing the immune‑related toxicities that have historically constrained this target class. The publication offers a detailed account of its distinct mechanism and biological profile, strengthening confidence in its differentiated clinical potential.
Roginolisib is now in a broad clinical development program that includes a randomized Phase II study in uveal melanoma, randomized Phase I/II trials in non‑small cell lung cancer and chronic lymphocytic leukemia, and additional Phase I/II studies in myelofibrosis and peripheral T‑cell lymphoma. More than 170 patients have been treated so far, underscoring both the maturity of the program and the ambition to address multiple malignancies with a single, mechanism‑driven agent.
